Risk Assessment Department, ANSES, 14 Rue Pierre et Marie Curie, 94701 Maisons-Alfort, France.
Univ-Lyon, CarMeN Laboratory, INSERM U1060, INRAé U1397, Université Claude Bernard Lyon 1, 69310 Pierre-Bénite, France.
Int J Mol Sci. 2022 Mar 15;23(6):3153. doi: 10.3390/ijms23063153.
This review provides an overview of the assessment of the endocrine disrupting (ED) properties of carbon disulfide (CS), following the methodology used at the European level to identify endocrine disruptors. Relevant in vitro, in vivo studies and human data are analyzed. The assessment presented here focuses on one endocrine activity, i.e., thyroid disruption, and two main adverse effects, neurotoxicity and cardiotoxicity. The data available on the different ED or non-ED modes of action (MoA), known to trigger these adverse effects, are described and the strength of evidence of the different MoA is weighted. We conclude that the adverse effects could be due to systemic toxicity rather than endocrine-mediated toxicity. This assessment illustrates the scientific and regulatory challenges in differentiating a specific endocrine disruption from an indirect endocrine effect resulting from a non-ED mediated systemic toxicity. This issue of evaluating the ED properties of highly toxic and reactive substances has been insufficiently developed by European guidance so far and needs to be further addressed. Finally, this example also raises questions about the capacity of the technics available in toxicology to address such a complex issue with certainty.
这篇综述按照欧洲确定内分泌干扰物的方法,概述了二硫化碳(CS)内分泌干扰特性的评估。分析了相关的体外、体内研究和人类数据。本文评估集中于一种内分泌活性,即甲状腺干扰,以及两种主要的不良影响,神经毒性和心脏毒性。对已知引发这些不良影响的不同内分泌干扰或非内分泌干扰作用模式(MoA)的数据进行了描述,并对不同 MoA 的证据强度进行了加权。我们的结论是,这些不良影响可能是由于全身毒性而不是内分泌介导的毒性。这种评估说明了从非内分泌介导的全身毒性的间接内分泌效应中区分特定内分泌干扰的科学和监管挑战。到目前为止,欧洲指南在评估高度毒性和反应性物质的内分泌特性方面还不够充分,需要进一步解决。最后,这个例子也提出了关于毒理学中现有技术是否有能力确定地解决如此复杂问题的疑问。